Research in pharmacogenomics points to a seismic shift in drug therapy, from a "one-size-fits-all" approach to a new era of personalized medicine, in which doctors will increasingly be able to prescribe the right drug at the right dose for the right person. Often used interchangeably with pharmacogenetics, pharmacogenomics is the study of how inherited genetic differences in humans influence individual responses to drugs. Courtesy of Genaissance PharmaceuticlsGerald F. Vovis Although a new worl

Better pay and richer research environments in the business sector lure young science grads away from academic labs Two years ago, when Thomas Malvar was finishing his doctorate in molecular immunology, he came to a major career crossroads. Should he go the traditional route and do his postdoctoral training in a university? Or should he follow a more adventurous path and do his postdoc in industry--a road that some of his professors warned was a professional dead end? Like a small but growin

Academic scientists, their futures uncertain because of budgetary woes in higher education, may be wondering if industrial research and development offers a safer haven. Meanwhile, bench researchers in industry, shaken by recent corporate downsizing and restructuring, may be looking for refuge in academia. The truth is, no scientific environment-not industry, government, or academia-has been spared the impact of the United States' long and deepening recession. The current job market in science

While the job market for scientists is generally dismal these days, you'd never know it from listening to Jonathan Meulbroek. A microbiologist and mucosal immunologist, Meulbroek is finishing a two-year postdoctoral position in infectious disease research at Eli Lilly and Co. in Indianapolis. Recently, he has had more invitations for job interviews than he has had time to accept. After receiving three job offers, he opted for a position with a major pharmaceutical firm. “I'm very pleased

Although investors are more cautious than they were in the go-go 1980s, sources of early-round backing flourish anew After a four-year slump, venture capital funds that provide early-round financial support, including seed money, to start-up biotechnology companies and other high-tech enterprises are reportedly starting to flourish again. "On the order of 100 venture capital funds are currently raising money," says Robert Mast, vice president of Venture Economics, Newark, N.J., a unit of Sec

The Wistar Institute in Philadelphia marks its 100th anniversary this year, but the mood at the nation's oldest independent biomedical research facility is hardly jubilant. The institute has been in turmoil for the last year, after the abrupt ouster of longtime director Hilary Koprowski, the famed virologist and immunologist who transformed Wistar from a dilapidated museum into a world-renowned research center. The commotion recently was stirred up further, when the 75-year-old Koprowski file

Were it not for World War II, Hilary Koprowski might be famous today as a concert pianist instead of a biomedical scientist whose achievements, including development of the first oral polio vaccine, have saved thousands of lives. Koprowski, who was born in Warsaw, Poland in 1916, at one time considered a career as a pianist, graduating from music conservatories in Warsaw and Rome. As the only child of the first female dental surgeon ever graduated from a Russian dental school, Koprowski grew

In 1892, when Gen. Isaac J. Wistar founded the institute that a century later still bears his name, his main intent was to make a home for the anatomical collection that belonged to his great-uncle Caspar Wistar, a University of Pennsylvania anatomist and physician. Fortunately, the general thought to add a few laboratories and research rooms to the museum on the first floor, which displayed such items as a great whale skeleton hanging from the ceiling. But though it was the general who fou